Member Info for PM2022

Sorry I meant works for TCB Capital Advisors.

Check out the reputation of the law firm.

Ken works for Culhane. Note what they offer:

We believe a key part of successfully navigating the transaction lifecycle is working with a client before the transaction process to identify and prevent potential operational, strategic, and financial issues. Our strategic mission is not just to execute corporate M&A and financing transactions, but to become a long-term partner to our clients and act as an extension of their internal capabilities.

Long term partner.

TCB Capital Advisors is serving as exclusive financial advisor:

https://www.tcbcapitaladvisors.com/strategic-advisory-board

Culhane Meadows is acting as TheoremRx’s legal counsel

https://www.cm.law/

The fact that you bring this up suggests an agenda. As I mentioned, Valirx no longer does clinical trials. Clinical trials are extremely expensive, costing many millions, so it’s a brilliant strategy that they have now avoided that. Raising funds for large trials on AIM can be difficult, which is why some of the companies like REDX ended up being delisted. Porky is well aware of this, as seen with 4D, which was burning over £1 million per week.

Like any company, they need to deliver results in a timely manner as the market cap needs to increase even with this low-risk strategy. On the positive side, I believe this is highly likely, considering all the upcoming news and the current low market cap. Once the market cap increases, any dilution here will be minimal as the cash burn here is very low for a biotech.

The strategy and management have changed. Point raised has zero relevance. We shall see what happens.

Whilst you are looking for the third one you list the dates of the 15 previous placings please?

That was years ago with a different BOD. Valirx no longer does clinical trials so no to raise many millions for this.

I doubt you have anything to invest anyway.

Have a great evening.

Irrelevant. What happens in the next 5 years is what matters. Enough for now.

We should wait for the news.

VAL401

WO/2014/049071

CN104797271

March 2020

The first Chinese patent granted for VAL401, granted claims include the composition of the formulation and use in the treatment of cancerous and non-cancerous disease linked to the mechanism of action

JP6734346

August 2020

Covers the use of VAL401 in the treatment of lung cancer

From an old discussion. Down to you to check but as far I know it should be in that range. I don't deal with patents to say for sure but Mark would know.

But don't forget potential royalty payments. Suzy stated to us it was likely just the one trial needed.

Therefore the potential revenue from 401 can be very significant not just the upfront payment and that will in turn attract decent investment. We all know how expensive cancer is to treat for each patient and how expensive the drugs are.

If I am correct as far as I know the patent life is about 12 years for 401 as it is a reformulated drug. (Double check). So fairly valuable and if it was not then no point Ambrose taking it on if sales were not likely to be significant.

Regarding salary, I don't really care. I am just looking at 6 months then I will evaluate the situation. We have plenty of news due then if they make progress on CLX or sign either 201 or 401 then i'll hang on longer most likely. If not i'll take what I believe could be a 10/20% hit as I don't see it moving down too much but yes this can hit 5-10 p in my opinion this year. They would have to do a really poor job to tank this to zero.

As below. Yes, potentially worth over 100k. Nobody said anything about 100k upfront payment but it is a contract for roughly that amount and possibly more.

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following contract award update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000 payment on completion of the first phase after 4 months and £10,500 on completion of the remaining in-vitro phase after a further 6 weeks. Successful candidates have the option to be evaluated in-vivo using selected PDCs through one of Inaphaea's partners.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "It is exciting to have secured this contract, which aligns our services with one of our strategic partners, and defines a good roadmap for future clients."

Mark Eccleston, CEO of ValiRx commented "This is an important contract for Inaphaea as it validates our partnered approach to offering full-service capabilities to our clients."

Should be interesting if he plays Sinner in the final.

I dispute it because your initial post stated you read from another poster which I noticed was Porky. It was then a week later you stated you got the information from a call so it seems to contradict versions.

Never mind. As long as we get value added news and build momentum.

No. I have no links to Valirx.

People state to discredit only.

They had a 100k contract in Nov, I think they will get a few more. Not a proven salary but even if it was as long as it can be justified through decent revenue. Mark himself will not be able to do the groundwork.

The main part is getting deals and improving the market cap although they need to ensure they have enough to avoid another placing before a deal. The cash burn must be one of the lowest for a biotech on AIM.

The lab is good because it helps with the evaluation projects.

Also it would be incredibly expensive paying for the development of CLX and would likely reduce the chances of success and would likely result in delays if it was not internal.

The lab will bring in good business and help fastrack projects in the hope of an earlier deal.

It is probably the best part of the strategy and Adam himself who knows the business was saying it was a good idea so hard to argue against that.

Not sure why you spend so much time here Rat. If you don't invest based on potential then don't invest. It is as simple as that.

But then you have been making promises for many years so i can see why Uncanny would not go for it. You stated many times you would support the next placing only if x,y or z was done such as if Suzy and Kevin were made to leave. You then spin it to something else. Not reliable.

Legal fees to complete an M and A merger would be significant. That in itself is a big commitment.

Mark stated he communicated with them regularly. It doesn't guarantee success but clearly they have a plan and Val has done significant DD. TheoremRx have invested time , money and resources so will likely do anything to get this over the line.

Val is no longer just about 201. We will get updates for CLX which is not currently priced in yet and it certainly is already worth millions at this stage. That should take the SP considerably higher as we approach the deal stage and could attract further interest from institutional investors.

401 deal might not include a large upfront payment but if they get it over the line and if the share price was not higher than where it is now and if Mark who is heavily invested decided to try and sell the company they would get a fairly decent offer. Possibly 5p plus even if 201 failed. Also it would attract institutional investment as only one trial is needed for commercialisation.

Don't forget they announced a 100k lab contract back in Nov 2024 and more will come. The cash burn of 2 million is very low for a biotech with so many promising assets. The revenue will likely reduce the cash burn to around 1.5 million. So all in all lots of news in the pipeline, low cash burn no debt and significantly undervalued.

To further add if we were not massively undervalued then why were all the shareholders so annoyed with a 6p placing which they all regarded as being very low. This is why board changes were made and it has dropped significantly since then and now has lots of news due and cash for 2025.

A great buy imo now that the CEO himself has purchased 6%. He knows more than all of us and is confident. If he felt he could not get at least one of the 3 being CLX, 201 or 401 over the line for a significant rise he would not invest as much.